Skip to content

Study · Randomized controlled trial · n = 302 · 2020

4 results

Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.

Blonde L, Belousova L, Fainberg U, Garcia-Hernandez PA, Jain SM, Kaltoft MS, Mosenzon O, Nafach J, Palle MS, Rea R

Diabetes, obesity & metabolism14 Feb 2020Cited by 44 (Europe PMC)

PMID31984646 (opens in a new tab)PMCIDPMC7317838 (opens in a new tab)DOI10.1111/dom.13978 (opens in a new tab)PepBankPUB-31984646
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on an SGLT2 inhibitor, add-on liraglutide lowered HbA1c more than placebo at week 26.

    In plain wordsIn adults with type 2 diabetes on an SGLT2 inhibitor, adding liraglutide lowered HbA1c more than adding placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at week 26
    Study

    n = 302

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.98%
    liraglutide

    Source sentences

    Summary
    Mean changes in HbA1c from baseline to week 26 with liraglutide (n = 202) and placebo (n = 100) were - 0.98% and - 0.30%, respectively (estimated treatment difference [ETD]: -0.68% [95% CI: -0.89, -0.48]; P < 0.001).
    1 context sentence
    Summary · context
    Patients with type 2 diabetes on a stable SGLT2i dose ± metformin (with HbA1c 7.0%-9.5% and body mass index [BMI] ≥ 20 kg/m2 ) were randomized 2:1 to add-on liraglutide 1.8 mg/day or placebo in this parallel, double-blind, multinational trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on an SGLT2 inhibitor, body weight change with liraglutide did not differ significantly from placebo at week 26.

    In plain wordsIn adults with type 2 diabetes on an SGLT2 inhibitor, weight change with liraglutide was not clearly different from placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody weight change at week 26
    Study

    n = 302

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean body weight changes from baseline were - 2.81 versus -1.99 kg, respectively (ETD: -0.82 kg [95% CI: -1.73, 0.09]; P = 0.077
    1 context sentence
    Summary · context
    Patients with type 2 diabetes on a stable SGLT2i dose ± metformin (with HbA1c 7.0%-9.5% and body mass index [BMI] ≥ 20 kg/m2 ) were randomized 2:1 to add-on liraglutide 1.8 mg/day or placebo in this parallel, double-blind, multinational trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on an SGLT2 inhibitor, more patients on liraglutide than on placebo reached HbA1c below 7.0%.

    In plain wordsIn adults with type 2 diabetes on an SGLT2 inhibitor, more people reached the HbA1c target with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion with HbA1c below 7.0%
    Study

    n = 302

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Patients with HbA1c <7.0%
    51.8%
    liraglutide
    Patients with HbA1c <7.0%
    23.2%
    placebo

    Source sentences

    Summary
    51.8% of liraglutide-treated patients achieved HbA1c < 7.0% versus 23.2% receiving placebo (odds ratio: 5.1 [95% CI: 2.67, 9.87]; P < 0.001).
    1 context sentence
    Summary · context
    Patients with type 2 diabetes on a stable SGLT2i dose ± metformin (with HbA1c 7.0%-9.5% and body mass index [BMI] ≥ 20 kg/m2 ) were randomized 2:1 to add-on liraglutide 1.8 mg/day or placebo in this parallel, double-blind, multinational trial.
  4. 04HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on an SGLT2 inhibitor, more patients on liraglutide than on placebo reported at least one treatment-emergent adverse event.

    In plain wordsIn adults with type 2 diabetes on an SGLT2 inhibitor, more people on liraglutide than on placebo reported at least one side effect.

    Peptide
    Liraglutide
    Outcome
    IncreaseTreatment-emergent adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Patients with >=1 TEAE
    66.3%
    liraglutide
    Patients with >=1 TEAE
    47%
    placebo

    Source sentences

    Summary
    More patients treated with liraglutide reported ≥1 treatment-emergent adverse events (66.3%) versus placebo (47.0%).
    1 context sentence
    Summary · context
    Patients with type 2 diabetes on a stable SGLT2i dose ± metformin (with HbA1c 7.0%-9.5% and body mass index [BMI] ≥ 20 kg/m2 ) were randomized 2:1 to add-on liraglutide 1.8 mg/day or placebo in this parallel, double-blind, multinational trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02964247

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Novo Nordisk A/Sn = 3033 Mar 2017 to 8 May 2018

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 17 Nov 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.